1. Market Research
  2. > Life Sciences Market Trends
Company Analysis : AbbVie

Company Analysis : AbbVie

  • July 2020
  • 72 pages
  • ID: 5955628
  • Format: PDF
  • Pharma Intelligence

Summary

Table of Contents

PharmaVitae explores AbbVie’s prescription pharmaceutical performance and outlook over 2019–29.

Snapshot
Overview – Declines in AbbVie’s flagship product Humira due to biosimilar competition will be offset by the company’s robust portfolio of launch drugs.
Key themes – [1] Biosimilar launches in Europe and other international markets have negatively impacted Humira’s growth, but the brand could grow in 2020 and should have revenue stability until US biosimilar launches in 2023 [2] AbbVie will see tremendous growth from Imbruvica, Skyrizi, Rinvoq, and Venclexta [3] Acquisition of Allergan, poised to close in 2020, will further diversify AbbVie’s revenues.

Model updates (25 February 2020)

Humira forecast adjusted lower in the US due to changes in reimbursement mix and lower new patient starts
Mavyret forecast adjusted lower due to market dynamics in HCV
Added Allergan drugs to AbbVie forecast due to closing of merger, including:

- Botox

- Restasis

- Vraylar

- Juvederm

- Linzess

- Lumigan

- Bystolic

- Alphagan

- Lo Loestrin

- AlloDerm

- Ozurdex

- Viibryd.
Model updates (25 February 2020)

Humira forecast adjusted higher due to stronger US trends only partially offset by continued biosimilar impact internationally
Skyrizi forecast adjusted higher due to strong initial launch in moderate-to-severe plaque psoriasis
Rinvoq forecast adjusted lower in the near-term due to launch trend in moderate-to-severe rheumatoid arthritis
Imbruvica forecast adjusted higher due to continued share gains in all lines of therapy in chronic lymphocytic leukemia and all approved indications
Venclexta forecast adjusted lower due to improved forecast for Imbruvica and market trends in chronic lymphocytic leukemia
Mavyret forecast adjusted lower due to lower treated patient volumes and increased competition in the US
Orilissa forecast adjusted higher due to contribution from potential uterine fibroids label expansion
Veliparib forecast pushed out to align with timeline for regulatory submission
Navitoclax forecast added
ABBV-951 forecast added.

Model updates (8 November 2019)

Humira forecast adjusted lower internationally due to continued biosimilar impact
Skyrizi forecast adjusted higher due to robust launch in the US; international forecast adjusted lower due to slower launch in the five major EU markets and Rest of World
Upadacitinib name changed to Rinvoq
Imbruvica forecast adjusted higher globally due to recent inflection in market share in first-line CLL.

Model updates (29 July 2019)

Humira sales adjusted lower due to size of biosimilar impact in the five major EU markets and Rest of World regions
Skyrizi sales adjusted higher due to pace of product launch
Mavyret sales adjusted significantly lower due to declining markets and pricing pressure in international geographies
Orilissa sales adjusted lower due to slower initial product ramp
Rova-T forecast removed due to disappointing safety and efficacy data from Phase II TRINITY study
Upadacitinib launch forecast updated
Atrasentan forecast removed.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Biosimilar Growth Hormones Global Market Report 2020-30: Covid 19 Growth and Change

  • $ 4000
  • November 2020
  • 200 pages

Biosimilar Growth Hormones Global Market Report 2020-30: COVID 19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global ...

  • World
  • Biosimilar
  • Industry analysis

Roche $ 3000 July 2020

Alexion $ 3000 July 2020

Amgen Company Analysis $ 3000 July 2020

Novo Nordisk $ 3000 July 2020

AbbVie $ 10000 April 2020


ref:plp2020

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on